Colonoscopy Clinical Trial
Official title:
Effect of Low-dose Dexmedetomidine on Hypotension in Colonoscopy：a Randomized Controlled Trial
104 patients who undergo painless colonoscopy from January 20,2024 to February 29,2024 will be randomized to two groups: propofol group and dexmedetomidine group. In the dexmedetomidine group,dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. In the propofol group, Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 during the whole process.
104 patients who undergo painless colonoscopy from January 20,2024 to February 29,2024 will be randomized to two groups: propofol group and dexmedetomidine group. In the dexmedetomidine group,dexmedetomidine is infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. In the propofol group, Propofol is administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1.For all patients, if Ramsay sedation scale score reach 3, colonoscope will be inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg will be administrated as the rescue dose if body movement occur during colonoscopy. The primary outcome is the occurrence of hypotension. Key secondary outcomes are time-weighted average (TWA), area under the threshold (AUT) and cumulative duration of hypotension, as well as the maximum reduction in BP. Other secondary outcomes include(1) the incidence of bradycardia, hypoxemia or body movement；(2) discharge time (from the end of colonoscopy to discharge); (3) patients and endoscopists' satisfaction score (using an 11-point Likert scale, with 0 indicating "very dissatisfied" and 10 indicating "very satisfied"); (4) the incidence of dizziness, fatigue, or nausea and vomiting ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04101097 -
Training and Validation of Models of Factors to Predict Inadequate Bowel Preparation Colonoscopy
|
||
| Completed |
NCT03247595 -
Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy
|
N/A | |
| Completed |
NCT04214301 -
An Open-Label Preference Evaluation of BLI800
|
Phase 4 | |
| Withdrawn |
NCT05754255 -
Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center
|
N/A | |
| Recruiting |
NCT02484105 -
Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction
|
Phase 4 | |
| Active, not recruiting |
NCT02264249 -
Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
|
N/A | |
| Terminated |
NCT01978509 -
The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies
|
N/A | |
| Completed |
NCT01964417 -
The Comparative Study Between Bowel Preparation Method
|
Phase 3 | |
| Recruiting |
NCT01685970 -
Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy
|
Phase 3 | |
| Completed |
NCT01518790 -
Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children
|
N/A | |
| Recruiting |
NCT00748293 -
Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet
|
N/A | |
| Completed |
NCT00779649 -
MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial
|
Phase 4 | |
| Completed |
NCT00671177 -
Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique
|
N/A | |
| Completed |
NCT00380497 -
Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children
|
Phase 4 | |
| Recruiting |
NCT00160823 -
Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients
|
Phase 3 | |
| Completed |
NCT00390598 -
PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy
|
Phase 2/Phase 3 | |
| Completed |
NCT00314418 -
Patient Position and Impact on Colonoscopy Time
|
N/A | |
| Completed |
NCT00209573 -
A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy
|
Phase 3 | |
| Completed |
NCT00427089 -
Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening
|
Phase 3 | |
| Completed |
NCT05823350 -
The Effect of Abdominal Massage on Pain and Distention After Colonoscopy
|
N/A |